HRP20110550T1 - Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji - Google Patents

Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji Download PDF

Info

Publication number
HRP20110550T1
HRP20110550T1 HR20110550T HRP20110550T HRP20110550T1 HR P20110550 T1 HRP20110550 T1 HR P20110550T1 HR 20110550 T HR20110550 T HR 20110550T HR P20110550 T HRP20110550 T HR P20110550T HR P20110550 T1 HRP20110550 T1 HR P20110550T1
Authority
HR
Croatia
Prior art keywords
compound
formula
accordance
cancer
preparation
Prior art date
Application number
HR20110550T
Other languages
English (en)
Croatian (hr)
Inventor
Alam Antoine
Bono Fran�oise
Duclos Olivier
Mc Cort Gary
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20110550T1 publication Critical patent/HRP20110550T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
HR20110550T 2007-06-13 2008-06-11 Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji HRP20110550T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704193A FR2917413B1 (fr) 2007-06-13 2007-06-13 Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
PCT/FR2008/000794 WO2009007536A2 (fr) 2007-06-13 2008-06-11 Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
HRP20110550T1 true HRP20110550T1 (hr) 2011-09-30

Family

ID=38961501

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110550T HRP20110550T1 (hr) 2007-06-13 2008-06-11 Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji

Country Status (28)

Country Link
US (2) US8263614B2 (enExample)
EP (1) EP2158194B1 (enExample)
JP (1) JP5346337B2 (enExample)
KR (1) KR20100019507A (enExample)
CN (1) CN101815715B (enExample)
AR (1) AR066955A1 (enExample)
AT (1) ATE509923T1 (enExample)
AU (1) AU2008274100B2 (enExample)
BR (1) BRPI0813809B1 (enExample)
CA (1) CA2690349C (enExample)
CO (1) CO6150157A2 (enExample)
CY (1) CY1111748T1 (enExample)
DK (1) DK2158194T3 (enExample)
EA (1) EA016552B1 (enExample)
ES (1) ES2366629T3 (enExample)
FR (1) FR2917413B1 (enExample)
HR (1) HRP20110550T1 (enExample)
IL (1) IL202677A (enExample)
IN (1) IN2009KN04279A (enExample)
MA (1) MA31674B1 (enExample)
ME (1) ME00957B (enExample)
MX (1) MX2009013514A (enExample)
MY (1) MY146939A (enExample)
NZ (1) NZ581883A (enExample)
PL (1) PL2158194T3 (enExample)
PT (1) PT2158194E (enExample)
SI (1) SI2158194T1 (enExample)
WO (1) WO2009007536A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2952934B1 (fr) 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
WO2012009097A1 (en) * 2010-06-17 2012-01-19 Cytokinetics, Inc. Methods of treating lung disease
WO2013072882A1 (en) * 2011-11-18 2013-05-23 Actelion Pharmaceuticals Ltd 2 -amino- 1, 8 -naphthyridine-3 -carboxamide derivatives as antimicrobial agents
CN116509854B (zh) * 2023-04-26 2025-05-23 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种萘啶酮衍生物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9800921A (es) 1995-08-02 1998-05-31 Chirotech Technology Ltd Quinolonas y su uso terapeutico.
CA2285352A1 (en) 1998-01-29 1999-08-05 Suntory Limited 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase iv inhibitory activity
DE19826050A1 (de) * 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
DE50213703D1 (de) 2001-05-08 2009-09-03 Bayer Schering Pharma Ag Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren
ATE303384T1 (de) 2001-05-24 2005-09-15 Merck Frosst Canada Inc 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
US7148357B2 (en) 2002-07-31 2006-12-12 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
WO2005118587A1 (en) * 2004-06-02 2005-12-15 Takeda Pharmaceutical Company Limited Indole derivative and use for treatment of cancer
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
FR2917413A1 (fr) 2008-12-19
HK1143590A1 (en) 2011-01-07
EA016552B1 (ru) 2012-05-30
ATE509923T1 (de) 2011-06-15
MA31674B1 (fr) 2010-09-01
CN101815715B (zh) 2014-10-08
CO6150157A2 (es) 2010-04-20
WO2009007536A2 (fr) 2009-01-15
EP2158194B1 (fr) 2011-05-18
FR2917413B1 (fr) 2009-08-21
CY1111748T1 (el) 2015-10-07
DK2158194T3 (da) 2011-09-12
MX2009013514A (es) 2010-01-27
ME00957B (me) 2012-06-20
BRPI0813809B1 (pt) 2021-05-25
IN2009KN04279A (enExample) 2015-08-28
AU2008274100A1 (en) 2009-01-15
US20100144782A1 (en) 2010-06-10
JP5346337B2 (ja) 2013-11-20
WO2009007536A3 (fr) 2009-03-19
NZ581883A (en) 2011-05-27
ES2366629T3 (es) 2011-10-24
PL2158194T3 (pl) 2011-10-31
US20120238598A1 (en) 2012-09-20
AU2008274100B2 (en) 2013-07-11
EP2158194A2 (fr) 2010-03-03
CN101815715A (zh) 2010-08-25
MY146939A (en) 2012-10-15
KR20100019507A (ko) 2010-02-18
EA201070010A1 (ru) 2010-06-30
IL202677A (en) 2014-12-31
SI2158194T1 (sl) 2011-10-28
US8263614B2 (en) 2012-09-11
BRPI0813809A2 (pt) 2020-02-04
CA2690349C (fr) 2015-11-24
JP2010529179A (ja) 2010-08-26
PT2158194E (pt) 2011-08-17
AR066955A1 (es) 2009-09-23
WO2009007536A8 (fr) 2010-01-07
CA2690349A1 (fr) 2009-01-15
US8586602B2 (en) 2013-11-19
IL202677A0 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
HRP20110515T1 (hr) Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji
HRP20140611T1 (hr) Inhibitori kinaze p70 s6
CA2121230A1 (en) 1,3-dihydro-2h-imidazo(4,5-b) quinolin-2-one derivatives
ME02892B (me) Hemijska jedinjenja
JP2016519091A (ja) 新規抗がん剤としてのキノリン誘導体
EP1073656A1 (en) Imidazo pyridine derivatives which inhibit gastric acid secretion
NZ605528A (en) Ip receptor agonist heterocyclic compounds
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
CN107074807A (zh) 用于抑制组蛋白脱甲基酶的组合物和方法
MX2007005189A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarinico m3.
NZ590784A (en) Pyrazolopyridine kinase inhibitors
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
IL175716A (en) 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
MEP23808A (en) Pyridine[3,4-b]pyrazinones
JP2016504365A5 (enExample)
HRP20160030T1 (hr) Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace)
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
AU7652101A (en) Cinnoline compounds
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
JP2005505618A5 (enExample)
CA2954999C (en) Fused quinoline compounds as pi3k, mtor inhibitors
MX2024003738A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
HRP20220446T1 (hr) Lijekovi inhibitora membranskog antigena specifičnog za prostatu (psma)
HRP20192279T1 (hr) Novi spojevi imidazopiridazina i njihova uporaba
MY195262A (en) Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-A]Pyrimidine Derivatives